|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
ImmunoGen, Inc.
| | | Phone: | (781) 895-0600 | Fax: | (781) 895-0611 | Year Established: | 1981 | Ticker: | IMGN | Exchange: | NASDAQ | Main Contact: | Blaine McKee, Executive VP & CBO | | Other Contacts: | Mark J. Enyedy, President & CEO Eric Guempel, VP, Product Strategy & Program Management James O'Leary, M.D., VP & CMO Theresa Wingrove, Ph.D., VP, RA Robert J. Lutz, Ph.D., VP, Translational Research and Development Godfrey Amphlett, Ph.D., VP, Process and Analytical Development Richard J. Gregory, Ph.D., Executive VP, Research CSO Anna Berkenblit, MD, MMSc, VP & CMO Craig Barrows, VP, General Counsel & Secretary
| | Company Description | ImmunoGen develops targeted anticancer therapeutics. The Company's ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound with ImmunoGen's ADC technology is Roche's Kadcyla, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. | |
|
|
|
|
|